logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Accepts Impax Pharma NDA Filing For IPX066 - Quick Facts

Impax Laboratories, Inc.'s (IPXL) branded products division, Impax Pharmaceuticals, said the U.S. Food and Drug Administration has accepted for filing the company's New Drug Application, or NDA, for IPX066 for the treatment of idiopathic Parkinson's disease submitted to the Agency on December 21, 2011. The Prescription Drug User Fee Date for a decision by the FDA is October 21, 2012.

IPX066 is a patented extended release capsule formulation of carbidopa-levodopa.

The NDA included data from three controlled Phase III studies and two open label extensions of IPX066 in both early and advanced Parkinson's disease.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Continuing efforts to normalize relations, President Barack Obama announced Wednesday the U.S. and Cuba will re-open embassies in each country's respective capitals later this month. Obama described the move as a demonstration that the U.S. and Cuba don't have to be imprisoned by the past. For pragmatic reasons, Senator Lindsay Graham no longer wants the party to "reaffirm our support for a Constitutional amendment defining marriage as the union of one man and one woman," as they did at the 2012 Republican Convention. The most "American" vehicle isn't Built Ford Tough. It's not in jingles sung by John Mellencamp or Bob Seger, and it probably isn't kickin' up backroads dust somewhere in the Heartland.
comments powered by Disqus
RELATED NEWS
Trade IPXL now with 
Follow RTT